Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 4Breast Neoplasms 4Melanoma 3Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Healthy Participants 2Advanced Solid Tumor 2cMET-dysregulated Advanced Solid Tumors 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Solid Tumor, Adult 1Solid Tumor 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Medulloblastoma 1Liver Cirrhosis 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Head and Neck Neoplasms 1Drug-drug Interaction,SHR3680 1Colorectal Neoplasms 1Advanced Solid Malignancies 1Advanced Pancreatic Cancer 1

Interventions

capmatinib 2Rosuvastatin Calcium 1Midazolam 1Digoxin 1Caffeine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
cMET-dysregulated Advanced Solid Tumors × Digoxin × Clear all
NCT02626234 2020-12-10

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

Novartis

Phase 1 Completed
32 enrolled
Other solid neoplasm

cMET-dysregulated Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡